Combination of clinical and molecular predictors to create a novel bio-clinical score that predicts outcome in relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL).

Bio-clinical model for event-free (EF) and overall survival (OS) of rrDLBCL patients.

Clinical predictors:
- Primary refractory disease
- Elevated serum LDH at relapse

Molecular predictors:
- MYC expression
- BLC2 expression

Analyses:
- Immunohistochemistry (IHC): 91 cases
- Digital gene expression profiling (GEP): 97 cases
- Fluorescence in situ hybridization (FISH): 67 cases

Multivariate analysis: 3-year EFS rate

<table>
<thead>
<tr>
<th>MYC, BLC2</th>
<th>0-1 (Low Risk)</th>
<th>2-4 (High Risk)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IHC</td>
<td>55%</td>
<td>16%</td>
</tr>
<tr>
<td>Digital GEP</td>
<td>46%</td>
<td>5%</td>
</tr>
<tr>
<td>FISH</td>
<td>42%</td>
<td>21%</td>
</tr>
</tbody>
</table>

Bosch et al., Haematologica, 2018